title: Lipoprotein lipase inhibits hepatitis C virus (HCV) infection by blocking virus cell entry.
abstract: A distinctive feature of HCV is that its life cycle depends on lipoprotein metabolism. Viral morphogenesis and secretion follow the very low-density lipoprotein (VLDL) biogenesis pathway and, consequently, infectious HCV in the serum is associated with triglyceride-rich lipoproteins (TRL). Lipoprotein lipase (LPL) hydrolyzes TRL within chylomicrons and VLDL but, independently of its catalytic activity, it has a bridging activity, mediating the hepatic uptake of chylomicrons and VLDL remnants. We previously showed that exogenously added LPL increases HCV binding to hepatoma cells by acting as a bridge between virus-associated lipoproteins and cell surface heparan sulfate, while simultaneously decreasing infection levels. We show here that LPL efficiently inhibits cell infection with two HCV strains produced in hepatoma cells or in primary human hepatocytes transplanted into uPA-SCID mice with fully functional human ApoB-lipoprotein profiles. Viruses produced in vitro or in vivo were separated on iodixanol gradients into low and higher density populations, and the infection of Huh 7.5 cells by both virus populations was inhibited by LPL. The effect of LPL depended on its enzymatic activity. However, the lipase inhibitor tetrahydrolipstatin restored only a minor part of HCV infectivity, suggesting an important role of the LPL bridging function in the inhibition of infection. We followed HCV cell entry by immunoelectron microscopy with anti-envelope and anti-core antibodies. These analyses demonstrated the internalization of virus particles into hepatoma cells and their presence in intracellular vesicles and associated with lipid droplets. In the presence of LPL, HCV was retained at the cell surface. We conclude that LPL efficiently inhibits HCV infection by acting on TRL associated with HCV particles through mechanisms involving its lipolytic function, but mostly its bridging function. These mechanisms lead to immobilization of the virus at the cell surface. HCV-associated lipoproteins may therefore be a promising target for the development of new therapeutic approaches.
authors: Institut Pasteur, Unité Hépacivirus et Immunité Innée, Département de Virologie, Paris, France.
authors: Patrick
authors: P
authors: Maillard
authors: Marine
authors: M
authors: Walic
authors: Philip
authors: P
authors: Meuleman
authors: Farzin
authors: F
authors: Roohvand
authors: Thierry
authors: T
authors: Huby
authors: Wilfried
authors: W
authors: Le Goff
authors: Geert
authors: G
authors: Leroux-Roels
authors: Eve-Isabelle
authors: EI
authors: Pécheur
authors: Agata
authors: A
authors: Budkowska
mesh_terms: D000818:Animals; D001483:Base Sequence; D045744:Cell Line, Tumor; D017931:DNA Primers; D016174:Hepacivirus / Q000472:pathogenicity*; D006801:Humans; D008071:Lipoprotein Lipase / Q000378:metabolism*; D008074:Lipoproteins / Q000378:metabolism; D008561:Membrane Fusion; D051379:Mice; D016513:Mice, SCID; D046529:Microscopy, Electron, Transmission; D016253:Microscopy, Immunoelectron; D016133:Polymerase Chain Reaction
chemical_list: D017931:DNA Primers; D008074:Lipoproteins; D008071:Lipoprotein Lipase